Based in South Korea, Peptron is a peptide-based pharmaceutical company committed to developing Sustained-release (SR) medications. We apply our sustained release expertise as we seek to develop injectables designed to help people living with complex health issues. Its proprietary spray-drying technology (SmartDepot?) efficiently guides the process from research to market, providing unique control over the drug release of various peptide-based or small-molecule injectables. With a simple and convenient manufacturing process, the unique spray-drying technique of SmartDepot? modifies the release profile from weekly to trimonthly. Peptron leverages its expertise in peptide-based pharmaceuticals to adopt a comprehensive approach to SR drug development. This sets us apart from competitors and offers significant advantages: formulation development (from once daily to weekly or monthly) for peptide and small molecule drugs, dose regimen modification from oral to SC, enhanced efficacy and safety margins, a quick development process, and a strong market position, and minimized toxicity (e.g., GI track) and maximized patient compliance. Our experience and references of sustained-release peptide drugs are: A. SR-Leuprolide (3.75mg, QM); ANDA (MA) stage generic drug, tri-monthly (Q3M) injectable formulation study ongoing B. SR-GLP-1 RAs; monthly injectable Semaglutide for Diabetes and Obesity C. SR-Exenatide (biweekly/weekly, 2mg); ph2 completed for PD and IND approved for IIH D. Chemical and other Peptide drug development